SwePub
Sök i SwePub databas

  Utökad sökning

Booleska operatorer måste skrivas med VERSALER

AND är defaultoperator och kan utelämnas

Träfflista för sökning "AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology) "

Sökning: AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Zamora-Ros, Raul, et al. (författare)
  • Tea and coffee consumption and risk of esophageal cancer : the European Prospective Investigation into Cancer and Nutrition (EPIC) study
  • 2014
  • Ingår i: International Journal of Cancer. - Wiley-Blackwell. - 0020-7136. ; 135:6, s. 1470-1479
  • Tidskriftsartikel (refereegranskat)abstract
    • Epidemiological data regarding tea and coffee consumption and risk of esophageal cancer (EC) is still inconclusive. We examined the association of tea and coffee consumption with EC risk among 442,143 men and women without cancer at baseline from 9 countries of the European Prospective Investigation into Cancer and Nutrition (EPIC). Tea and coffee intakes were recorded using country-specific validated dietary questionnaires. Cox regression models were used to analyze the relationships between tea and coffee intake and EC risk. During a mean follow-up of 11.1 years, 339 participants developed EC, of which 142 were esophageal adenocarcinoma (EAC) and 174 were esophageal squamous cell carcinoma (ESCC). In the multivariable models, no significant associations between tea (mostly black tea), and coffee intake and risk of EC, EAC and ESCC were observed. In stratified analyses, among men coffee consumption was inversely related to ESCC (HR for comparison of extreme tertiles 0.42, 95% CI 0.20-0.88; P-trend=0.022), but not among women. In current smokers, a significant and inverse association was observed between ESCC risk and tea (HR 0.46, 95% CI 0.23-0.93; P-trend=0.053) and coffee consumption (HR 0.37, 95% CI 0.19-0.73; P-trend=0.011). However, no statistically significant findings were observed using the continuous variable (per 100mL/d). These data did not show a significant association between tea and coffee consumption and EC, EAC and ESCC, although a decreased risk of ESCC among men and current smokers is suggested, but need to be confirmed in further prospective studies including more cases.
  •  
32.
  • Sandén, Emma, et al. (författare)
  • Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.
  • 2015
  • Ingår i: Journal of Neurooncology. - Springer. - 1573-7373. ; 123:1, s. 1-13
  • Tidskriftsartikel (refereegranskat)abstract
    • The CD24 glycoprotein is a mediator of neuronal proliferation, differentiation and immune suppression in the normal CNS, and a proposed cancer biomarker in multiple peripheral tumor types. We performed a comparative analysis of CD24 gene expression in a large cohort of pediatric and adult brain tumors (n = 813), and further characterized protein expression in tissue sections (n = 39), primary brain tumor cultures (n = 12) and a novel orthotopic group 3 medulloblastoma xenograft model. Increased CD24 gene expression was demonstrated in ependymomas, medulloblastomas, anaplastic astrocytomas and glioblastomas, although medulloblastomas displayed higher expression than all other tumor entities. Preferential expression of CD24 in medulloblastomas was confirmed at protein level by immunostaining and computerized image analysis of cryosections. Morphologies and immunophenotyping of CD24(+) cells in tissue sections tentatively suggested disparate functions in different tumor subsets. Notably, protein staining of medulloblastoma cells was associated with prominent cytoplasmic and membranous granules, enabling rapid and robust identification of medulloblastoma cells in clinical tissue samples, as well as in experimental model systems. In conclusion, our results implicate CD24 as a clinically and experimentally useful medulloblastoma immunomarker. Although our results encourage further functional studies of CD24 as a potential molecular target in subsets of brain tumors, the promiscuous expression of CD24 in vivo highlights the importance of specificity in the future design of such targeted treatment.
  •  
33.
  • Lönnbro-Widgren, Jennie, et al. (författare)
  • Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy
  • 2015
  • Ingår i: Clinical Kidney Journal. - 1753-0784 .- 1753-0792. ; 8:4, s. 433-439
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: In idiopathic membranous nephropathy (MN), antibodies directed towards the glomerular phospholipase A2 receptor (PLA2R) have mainly been reported to be of IgG4 subclass. However, the role of the different IgG subclasses in the pathogenesis of MN, both in idiopathic MN and in secondary cases, is still unclear. In this retrospective study, we test the hypothesis that the absence of glomerular IgG4 and PLA2R in patients with MN indicates malignant disease. Methods: The distribution pattern of glomerular IgG subclasses and PLA2Rwas studied in 69 patients with idiopathicMNand 16 patients with malignancy-associated MN who were followed up for a mean of 83 months. Results: A significant correlation between the absence of IgG4 and PLA2R and malignancy-associatedMNwas found. Thus, IgG4 was positive in 45 of 69 patients (65%) with idiopathicMNbut only in 5 of 16 patients (31%) with malignancy-associated MN. The other IgG subclasses did not differ statistically between the groups, IgG2-positivity being present in more than 94% of patients in both groups. Thirty-five of 63 patients (56%) with idiopathic MN and 3 of 16 (19%) patients with malignancy-associated MN had glomerular deposits of PLA2R. Conclusions: We have found that the absence of glomerular IgG4 and PLA2R iscommonin patients with malignancy-associated MN. In our material, IgG2 could not be used as a marker of underlying malignant disease. Finally, neither IgG1 nor IgG3 seems to be involved in the pathogenesis of MN. © The Author 2015.
  •  
34.
  • Bentmar Holgersson, Magdalena, et al. (författare)
  • Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
  • 2017
  • Ingår i: Cancer Causes & Control. - 0957-5243. ; 28:3, s. 227-233
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. Results: The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47–1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51–0.90; p = 0.008). Conclusions: Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.
35.
  • Grundberg, Ida, 1982-, et al. (författare)
  • Diagnostic mutation testing in situ in routine FFPE tissue sections for treatment prediction in clinical oncology
  • ????
  • Annan publikation (övrigt vetenskapligt)abstract
    • Activating mutations in the KRAS gene are present in different cancer types and are strongly associated with resistance to epidermal growth factor receptor (EGFR) inhibitor therapy. Hence there is a requirement for sensitive KRAS mutation analysis to determine the most suitable treatment for the patients. Also, little is known about the impact of tumor heterogeneity with regard to KRAS mutation status in different sub-clones during tumorigenesis, and if this is important for treatment response and prognosis. To improve the diagnostic accuracy, we developed an RNA-based genotyping assay that targets KRAS-mutations in codon 12 and 13 in situ on tissue samples by the use of multiple mutation specific padlock probes and rolling-circle amplification. Thus, the distribution of wild-type (green rolling-circle products) and mutated (red rolling-circle products) KRAS alleles can be determined for single cancer cells in different parts of a heterogeneous tumor without the use of microdissection. We demonstrate reliable detection of KRAS point mutations on cytologic tumor imprints as well as on fresh frozen and formalin-fixed paraffin-embedded tissue sections from colorectal and lung cancer. This in situ method offers single cell mutation detection for diagnostics and holds great promise as a tool to investigate the role of oncogenic mutations in complex tumor tissues.
  •  
36.
  • Hedén, Lena, et al. (författare)
  • Children’s self-reports of fear and pain levels during needle procedures
  • 2020
  • Ingår i: Nursing Open. - 2054-1058. ; 7:1, s. 376-382
  • Tidskriftsartikel (refereegranskat)abstract
    • AimThe objective was to determine the levels of and potential relationships between, procedure‐related fear and pain in children.DesignClinical based cross‐sectional.MethodsNinety children aged between 7–18 years were included consecutively and self‐reported levels of pain and fear on a 0–100 mm visual analogue scales (VAS) when undergoing routine needle insertion into a subcutaneously implanted intravenous port following topical anaesthesia.ResultsThe needle‐related fear level was reported to be as high as the needle‐related pain level (mean VAS: 14 mm and 12 mm, respectively, N = 90). With fear as the dependent variable, age and pain were significantly associated and explained 16% of the variance. With pain as the dependent variable, fear was significantly associated and explained 11% of the variance. A post hoc analysis indicated that younger children reported their fear levels to be higher than their pain levels.
37.
  • Zainuddin, Norafiza, 1978-, et al. (författare)
  • Quantitative evaluation of p16INK4a promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma
  • 2011
  • Ingår i: Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. - 0145-2126 .- 1873-5835. ; 35:4, s. 438-443
  • Tidskriftsartikel (refereegranskat)abstract
    • The p16INK4a tumor suppressor gene can be inactivated by a variety of events including promoter hypermethylation. In diffuse large B-cell lymphoma (DLBCL), p16INK4a methylation has been associated with advanced disease stage and higher IPI. The prognostic impact of p16INK4a methylation in DLBCL remains unclear; however, it has been suggested to correlate with inferior outcome. To further investigate the clinical impact of p16INK4a methylation in DLBCL, promoter methylation of this gene was assessed quantitatively by pyrosequencing. Forty-two of 113 (37%) DLBCL patients with methylation level above 5% were categorized as methylated and subsequently divided into low, intermediate and high methylation categories. Overall, no association was shown between the extent of p16INK4a methylation and patients’ clinical characteristics, except disease stage (P=0.049). Moreover, we could not reveal any impact of p16INK4a methylation on lymphoma-specific survival. Although >25% of p16INK4a methylation correlated with a better progression-free survival (P=0.048), the significance of this finding, if any, needs to be further investigated. In conclusion, our finding questions the role of p16INK4a promoter methylation as a negative prognostic factor in DLBCL.
  •  
38.
  • Ge, Chenjie, et al. (författare)
  • Enlarged Training Dataset by Pairwise GANs for Molecular-Based Brain Tumor Classification
  • 2020
  • Ingår i: IEEE Access. - 2169-3536. ; 8:1, s. 22560-22570
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper addresses issues of brain tumor subtype classification using Magnetic Resonance Images (MRIs) from different scanner modalities like T1 weighted, T1 weighted with contrast-enhanced, T2 weighted and FLAIR images. Currently most available glioma datasets are relatively moderate in size, and often accompanied with incomplete MRIs in different modalities. To tackle the commonly encountered problems of insufficiently large brain tumor datasets and incomplete modality of image for deep learning, we propose to add augmented brain MR images to enlarge the training dataset by employing a pairwise Generative Adversarial Network (GAN) model. The pairwise GAN is able to generate synthetic MRIs across different modalities. To achieve the patient-level diagnostic result, we propose a post-processing strategy to combine the slice-level glioma subtype classification results by majority voting. A two-stage course-to-fine training strategy is proposed to learn the glioma feature using GAN-augmented MRIs followed by real MRIs. To evaluate the effectiveness of the proposed scheme, experiments have been conducted on a brain tumor dataset for classifying glioma molecular subtypes: isocitrate dehydrogenase 1 (IDH1) mutation and IDH1 wild-type. Our results on the dataset have shown good performance (with test accuracy 88.82%). Comparisons with several state-of-the-art methods are also included.
39.
  • Andritsch, E., et al. (författare)
  • ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review
  • 2017
  • Ingår i: Critical Reviews in Oncology Hematology. - 1040-8428. ; 110, s. 94-105
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific tumour type. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe. Sarcomas - which can be classified into soft tissue and bone sarcomas - are rare, but all rare cancers make up more than 20% of cancers in Europe, and there are substantial inequalities in access to high-quality care. Sarcomas, of which there are many subtypes, comprise a particularly complex and demanding challenge for healthcare systems and providers. This paper presents essential requirements for quality cancer care of soft tissue sarcomas in adults and bone sarcomas. High-quality care must only be carried out in specialised sarcoma centres (including paediatric cancer centres) which have both a core multidisciplinary team and an extended team of allied professionals, and which are subject to quality and audit procedures. Access to such units is far from universal in all European countries. It is essential that, to meet European aspirations for high-quality comprehensive cancer control, healthcare organisations implement the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis and follow-up, to treatment, to improve survival and quality of life for patients. Conclusion: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality service for soft tissue sarcomas in adults and bone sarcomas. The ECCO expert group is aware that it is not possible to propose a 'one size fits all' system for all countries, but urges that access to multidisciplinary teams is guaranteed to all patients with sarcoma. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
  •  
40.
  • Alfonzo, Emilia, et al. (författare)
  • No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study
  • 2019
  • Ingår i: European Journal of Cancer. - 0959-8049. ; 116, s. 169-177
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: The aim of the study was to compare overall survival (OS) and disease-free survival (DFS) after open and robotic radical hysterectomy for early-stage cervical cancer. Patients and methods: This was a nationwide population-based cohort study on all women with cervical cancer stage IA1-IB of squamous, adenocarcinoma or adenosquamous histological subtypes, from January 2011 to December 2017, for whom radical hysterectomy was performed. The Swedish Quality Register of Gynaecologic Cancer was used for identification. To ensure quality and conformity of data and to disclose patients not yet registered, hospital registries were reviewed and validated. Cox and propensity score regression analysis and univariable and multivariable regression analysis were performed in regard to OS and DFS. Results: There were 864 women (236 open and 628 robotic) included in the study. The 5-year OS was 92% and 94% and DFS was 84% and 88% for the open and robotic cohorts, respectively. The recurrence pattern was similar in both groups. Using propensity score analysis and matched cohorts of 232 women in each surgical group, no significant differences were seen in survival: 5-year OS of 92% in both groups (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.50–2.01) and DFS of 85% vs 84% in the open and robotic cohort, respectively (HR, 1.08; 95% CI, 0.66–1.78). In univariable and multivariable analysis with OS as the end-point, no significant factors were found, and in regard to DFS, tumour size (p < 0.001) and grade 3 (p = 0.02) were found as independent significant risk factors. Conclusion: In a complete nationwide population-based cohort, where radical hysterectomy for early-stage cervical cancer is highly centralised, neither long-term survival nor pattern of recurrence differed significantly between open and robotic surgery.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (3497)
Typ av publikation
tidskriftsartikel (10452)
doktorsavhandling (562)
forskningsöversikt (473)
konferensbidrag (456)
annan publikation (150)
bokkapitel (109)
visa fler...
rapport (17)
bok (9)
samlingsverk (redaktörskap) (6)
licentiatavhandling (4)
recension (3)
proceedings (redaktörskap) (2)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (10382)
övrigt vetenskapligt (2161)
populärvet., debatt m.m. (26)
Författare/redaktör
Olsson, Håkan, (329)
Riboli, Elio (328)
Trichopoulou, Antoni ... (317)
Tumino, Rosario (297)
Overvad, Kim (292)
Boeing, Heiner (282)
visa fler...
Kaaks, Rudolf (275)
Khaw, Kay-Tee (262)
Borg, Åke, (262)
Jirström, Karin, (243)
Tjonneland, Anne (240)
Hemminki, Kari, (239)
Palli, Domenico, (225)
Sánchez, Maria-José (213)
Glimelius, Bengt, (212)
Manjer, Jonas (211)
Weiderpass, Elisabet ... (204)
Boutron-Ruault, Mari ... (203)
Stattin, Pär, (202)
Tjønneland, Anne (200)
Bueno-de-Mesquita, H ... (195)
Vineis, Paolo (190)
Panico, Salvatore, (187)
Fernö, Mårten, (181)
Forssell-Aronsson, E ... (165)
Hallmans, Göran, (160)
Trichopoulos, Dimitr ... (158)
Sundquist, Jan, (148)
Clavel-Chapelon, Fra ... (144)
Travis, Ruth C (144)
Dasu, Alexandru (143)
Bjartell, Anders, (141)
Bendahl, Pär Ola, (140)
Barricarte, Aurelio (140)
Ardanaz, Eva, (137)
Holmberg, Lars, (136)
Jenab, Mazda (136)
Henriksson, Roger, (132)
Toma-Dasu, Iuliana, (130)
Nilbert, Mef, (129)
Sundquist, Kristina, (128)
Rydén, Lisa, (127)
Dorronsoro, Miren (123)
Peeters, Petra H (121)
Olsen, Anja (119)
Mertens, Fredrik, (119)
Pontén, Fredrik, (118)
Lund, Eiliv (116)
Sacerdote, Carlotta (116)
Peeters, Petra H. M. (116)
visa färre...
Lärosäte
Lunds universitet (5763)
Uppsala universitet (2731)
Karolinska Institutet (2609)
Göteborgs universitet (2282)
Umeå universitet (2142)
Linköpings universitet (816)
visa fler...
Örebro universitet (593)
Stockholms universitet (242)
Chalmers tekniska högskola (155)
Kungliga Tekniska Högskolan (130)
Högskolan i Jönköping (84)
Ersta Sköndal Bräcke högskola (73)
Högskolan i Skövde (71)
Linnéuniversitetet (44)
Sveriges Lantbruksuniversitet (33)
Malmö universitet (31)
Mittuniversitetet (28)
Sophiahemmet Högskola (25)
Mälardalens högskola (24)
Högskolan Kristianstad (20)
Högskolan Dalarna (20)
Högskolan Väst (16)
Röda Korsets Högskola (16)
Karlstads universitet (15)
Högskolan i Borås (12)
Gymnastik- och idrottshögskolan (11)
Södertörns högskola (10)
Högskolan i Gävle (8)
Högskolan i Halmstad (4)
Blekinge Tekniska Högskola (4)
RISE (3)
Luleå tekniska universitet (1)
Försvarshögskolan (1)
visa färre...
Språk
Engelska (11851)
Svenska (147)
Danska (3)
Spanska (3)
Isländska (3)
Annat språk (3)
visa fler...
Norska (2)
Tyska (1)
Odefinierat språk (1)
Polska (1)
Kinesiska (1)
Ukrainska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12244)
Naturvetenskap (404)
Samhällsvetenskap (148)
Teknik (75)
Lantbruksvetenskap (27)
Humaniora (16)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy